B

BioXcel Therapeutics
D

BTAI

1.94000
USD
0.01
(0.52%)
مغلق
حجم التداول
921
الربح لكل سهم
-6
العائد الربحي
-
P/E
-0
حجم السوق
11,748,729
أصول ذات صلة
A
ALLO
-0.00500
(-0.42%)
1.18500 USD
C
CRSP
0.455
(0.88%)
52.120 USD
E
EDIT
0.02000
(0.78%)
2.57000 USD
GILD
GILD
-0.760
(-0.68%)
110.760 USD
N
NTLA
-0.020
(-0.19%)
10.710 USD
PFE
PFE
0.110
(0.43%)
25.440 USD
REGN
REGN
-0.69
(-0.13%)
546.88 USD
S
SGMO
0.00200
(0.38%)
0.53200 USD
VRTX
VRTX
2.24
(0.49%)
459.27 USD
المزيد
الأخبار المقالات

العنوان: BioXcel Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.